205 related articles for article (PubMed ID: 11748952)
1. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease.
Danielsson G; Jungbeck C; Peterson K; Norgren L
Eur J Vasc Endovasc Surg; 2002 Jan; 23(1):73-6. PubMed ID: 11748952
[TBL] [Abstract][Full Text] [Related]
2. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
Lyseng-Williamson KA; Perry CM
Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
Kakkos SK; Nicolaides AN
Int Angiol; 2018 Apr; 37(2):143-154. PubMed ID: 29385792
[TBL] [Abstract][Full Text] [Related]
4. Daflon 500 mg: symptoms and edema clinical update.
Ramelet AA
Angiology; 2005; 56 Suppl 1():S25-32. PubMed ID: 16193223
[TBL] [Abstract][Full Text] [Related]
5. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.
Jantet G
Angiology; 2002; 53(3):245-56. PubMed ID: 12025911
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Olszewski W
Angiology; 2000 Jan; 51(1):25-9. PubMed ID: 10667640
[TBL] [Abstract][Full Text] [Related]
7. VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease.
Mezalek ZT; Feodor T; Chernukha L; Chen Z; Rueda A; Sánchez IE; Ochoa AJG; Chirol J; Blanc-Guillemaud V; Lohier-Durel C; Ulloa JH
Adv Ther; 2023 Nov; 40(11):5016-5036. PubMed ID: 37728696
[TBL] [Abstract][Full Text] [Related]
8. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial.
Belczak SQ; Sincos IR; Campos W; Beserra J; Nering G; Aun R
Phlebology; 2014 Aug; 29(7):454-60. PubMed ID: 23761871
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial.
Rabe E; Agus GB; Roztocil K
Int Angiol; 2015 Oct; 34(5):428-36. PubMed ID: 25972136
[TBL] [Abstract][Full Text] [Related]
10. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids.
Jantet G
Angiology; 2000 Jan; 51(1):31-7. PubMed ID: 10667641
[TBL] [Abstract][Full Text] [Related]
11. [Edema as a measure for severity of chronic venous insufficiency and efficacy of its treatment].
Sapelkin SV
Angiol Sosud Khir; 2008; 14(3):79-81. PubMed ID: 19791434
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of micronized purified flavonoid fraction: an overview.
Struckmann JR
J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
[TBL] [Abstract][Full Text] [Related]
13. Clinical acceptability study of once-daily versus twice-daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial.
Kirienko A; Radak D
Int Angiol; 2016 Aug; 35(4):399-405. PubMed ID: 26576663
[TBL] [Abstract][Full Text] [Related]
14. The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes.
Jiang ZM; Cao JD
Curr Med Res Opin; 2006 Jun; 22(6):1141-7. PubMed ID: 16846547
[TBL] [Abstract][Full Text] [Related]
15. Global venous function correlates better than duplex derived reflux to clinical class in the evaluation of chronic venous disease.
Danielsson G; Norgren L; Jungbeck C; Peterson K
Int Angiol; 2003 Jun; 22(2):177-81. PubMed ID: 12865884
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
Hnátek L
Vnitr Lek; 2015 Sep; 61(9):807-14. PubMed ID: 26465280
[TBL] [Abstract][Full Text] [Related]
17. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study.
Shoab SS; Scurr JH; Coleridge-Smith PD
Eur J Vasc Endovasc Surg; 1999 Oct; 18(4):334-8. PubMed ID: 10550269
[TBL] [Abstract][Full Text] [Related]
18. Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New Evidence.
Ulloa JH
Adv Ther; 2019 Mar; 36(Suppl 1):20-25. PubMed ID: 30758743
[TBL] [Abstract][Full Text] [Related]
19. [Comparative efficacy of various methods of treatment of chronic venous oedema in real clinical practice].
Bogachev VI; Boldin BV; Turkin PI; Samenkov AI;
Angiol Sosud Khir; 2021; 27(3):77-83. PubMed ID: 34528591
[TBL] [Abstract][Full Text] [Related]
20. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
Tsouderos Y
Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
